Q-omics provides the consensus-scored EPHA6 profile across patient tissues and cancer cell-line models. EPHA6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, EPHA6 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, EPHA6 RNA expression shows 16,532 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KIRC, and GBM as cancer lineages where EPHA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPHA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPHA6 survival associations across molecular data types. EPHA6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPHA6 RNA expression–survival associations across cancer types. High EPHA6 expression shows unfavorable associations in UCEC, READ, BLCA and COAD, but favorable associations in LGG and BRCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for EPHA6 RNA expression.
This table summarizes EPHA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EPHA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPHA6 shows lower tumor expression in THCA, COAD, STAD, KICH and BLCA and higher tumor expression in KIRC. The KIRC box plot shows higher EPHA6 RNA expression in tumor versus normal tissue (log2 FC = +1.072, t-test p < 0.001).
This table shows molecular features associated with EPHA6 in patient tissues and cancer cell lines. In patient samples, EPHA6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, EPHA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
